Tech-enabled sleep health company Nox Health was the highest bidder for Pear Therapeutics' Somryst assets at an auction last month that followed the prescription digital therapeutic company's bankruptcy in April.
Nox bid $3.9 million for Pear's FDA-cleared prescription digital therapeutic Somryst, which uses cognitive behavioral therapy for insomnia to train the brain and body to sleep.
Sigurjon...
Prescription digital therapeutics startup Pear Therapeutics announced an $80 million Series D round this morning headed by SoftBank Vision Fund 2.
The raise included funds from new backers Forth Management, Pilot House, Sarissa Capital, Shanda Group and QUAD Investment Management, as well as from returning investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis,...
Pear Therapeutics announced today the availability of its prescription digital therapeutic for chronic insomnia in adults over the age of 22, called Somryst.
Somryst uses cognitive behavioral therapy for insomnia (CBTi) to train the brain and body to sleep. Over the course of the patient’s program, the therapy guides them through lessons and challenges, including algorithm-driven sleep...
Pear Therapeutics highlighted data today from two studies of a digital cognitive behavioral therapy that acted as the precursor for Somryst, the prescription digital therapeutic for adults with chronic insomnia that was the first to pass through the FDA's Pre-Cert pilot pathway.
The first, a randomized controlled trial of 1,149 Australian adults with insomnia and depressive symptoms, suggested...
Decentralized digital therapeutic trial. Pear Therapeutics has enrolled the first participant in the DREAM study, an open-label trial of its Somryst prescription digital therapeutic for chronic insomnia.
Conducted as a decentralized trial, the effort will recruit U.S. adults aged 22 to 75 years who have an Insomnia Severity Index score of 8 or higher, as well as at least three months of insomnia...
Yesterday, Pear Therapeutics announced the regulatory clearance of Somryst, its prescription digital therapeutic for chronic insomnia. And while the product is noteworthy for these patients and Pear's broader business, it also stands as a major milestone for the digital health industry – the first product to be evaluated throught the FDA's Digital Health Software Precertification Program.
Now...
Pear Therapeutics announced this morning that Somryst, its prescription digital therapeutic for adults with chronic insomnia, has received marketing authorization from the FDA.
The treatment provides cognitive behavioral therapy for insomnia (CBTi) alongside personalized, algorithm-generated sleep restriction recommendations. The digital therapeutic was reviewed through the agency's 510(k)...
Prescription digital therapeutics company Pear Therapeutics announced late last week that it has filed an FDA marketing authorization for Somryst, its digital cognitive behavioral therapy for the treatment of adults with chronic insomnia and depression.
While an approval from the agency would mark the third authorized prescription digital therapeutic for Pear — behind reSET for substance use...
